The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
The migraine drugmaker has been sending weak technical signals for a few months now.
Volume has picked up dramatically since a selloff in the online health services provider began, and it could get worse.
I hate chasing a stock but it looks like I need to get with the program.
Since we don't have a breakout, I would stay with a half-size approach on any trade here.
Let's see if it's time to jump back on the bike.
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Let's review the charts and indicators.
More people seeking more healthcare and medical attention will create a rising tide for GMRE's addressable market.
Let's check out the charts and indicators.